Last updated: 22 July 2019 at 10:14pm EST

Kathleen M O Donnell Net Worth

The estimated Net Worth of Kathleen M O Donnell is at least $936 mil dollars as of 25 October 2004. Kathleen Donnell owns over 2,500 units of Biodelivery Sciences International stock worth over $935,766 and over the last 20 years Kathleen sold BDSI stock worth over $0.

Kathleen Donnell BDSI stock SEC Form 4 insiders trading

Kathleen has made over 16 trades of the Biodelivery Sciences International stock since 2004, according to the Form 4 filled with the SEC. Most recently Kathleen bought 2,500 units of BDSI stock worth $8,875 on 25 October 2004.

The largest trade Kathleen's ever made was buying 25,000 units of Biodelivery Sciences International stock on 27 August 2004 worth over $71,750. On average, Kathleen trades about 8,082 units every 4 days since 2004. As of 25 October 2004 Kathleen still owns at least 167,400 units of Biodelivery Sciences International stock.

You can see the complete history of Kathleen Donnell stock trades at the bottom of the page.

What's Kathleen Donnell's mailing address?

Kathleen's mailing address filed with the SEC is C/O MCCABE & O'DONNELL, 3101 NORTH CENTRAL AVENUE, SUITE 700, PHOENIX, AZ, 85012.

Insiders trading at Biodelivery Sciences International

Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott, eHealthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.

What does Biodelivery Sciences International do?

BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.

Complete history of Kathleen Donnell stock trades at Biodelivery Sciences International

Acionista maioritário	Trans. Transação	Preço total
Kathleen M O Donnell 10% proprietário	Comprar	$8,875 25 Oct 2004
Kathleen M O Donnell 10% proprietário	Comprar	$26,625 18 Oct 2004
Kathleen M O Donnell 10% proprietário	Comprar	$20,450 12 Oct 2004
Kathleen M O Donnell 10% proprietário	Comprar	$34,100 6 Oct 2004
Kathleen M O Donnell 10% proprietário	Comprar	$14,000 4 Oct 2004
Kathleen M O Donnell 10% proprietário	Comprar	$14,700 30 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$7,350 24 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$7,225 22 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$28,809 20 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$20,850 15 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$7,375 13 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$109,275 9 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$29,800 3 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$43,350 1 Sep 2004
Kathleen M O Donnell 10% proprietário	Comprar	$71,750 27 Aug 2004
Kathleen M O Donnell 10% proprietário	Comprar	$56,000 26 Aug 2004

Biodelivery Sciences International executives and stock owners

Biodelivery Sciences International executives and other stock owners filed with the SEC include:

Scott Plesha,
President, Chief Commercial Officer
Mary Coelho,
Chief Financial Officer, Treasurer
Thomas Smith,
Chief Medical Officer
James Vollins,
Chief Compliance Officer, General Counsel, Corporate Secretary
Scott M. Plesha,
Pres & Chief Commercial Officer
James Vollins J.D.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec.
Dr. Thomas B. Smith FAAFP, M.D.,
Chief Medical Officer
Vanila Singh,
Independent Director
Mark Sirgo,
Vice Chairman of the Board
Todd Davis,
Independent Director
Peter Greenleaf,
Independent Chairman of the Board
William Watson,
Independent Director
Kevin Kotler,
Independent Director
Kevin Ostrander,
Senior Vice President - Business Development
Joseph Lockhart,
Senior Vice President - Operations
Jeffrey Bailey,
Chief Executive Officer
Dr. Jeff Katz,
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
Dr. Arthur G. Lipman PharmD,
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
Dr. Bill McCarberg,
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board
John Golubieski,
CFO & Chief Accounting Officer
Niraj Vasisht,
Chief Technology Officer
Samuel P Jr Sears,
Director
Barry I Feinberg,
Director
Charles Bramlage,
Director
William B Stone,
Director
Francis E Jr Odonnell,
Director
Thomas D'alonzo,
Director
Healthcare Master Fund Ltd ...,
Timothy Tyson,
Director
W. Mark Watson,
Director
Kevin Broadfin Healthcare M...,
Herm Cukier,
Chief Executive Officer
John J Shea,
Director
Iv Llc Ramsay David Russ Le...,
Capital Group Ii Llc Hopkins,
10% owner
Allan Pearce,
Director
James R Butler,
Director
Paolantonio Ernest Robert De,
CFO and Secretary
Associates, L.P. Elliott,
10% owner
James A Mcnulty,
Chief Financial Officer
William Poole,
Director
Kathleen M Tr Irrev Tr 1 Fb...,
10% owner
Raphael J Mannino,
Executive Vice President & CSO
Donald Ferguson,
Director
Iv Llccdc Operations Llc Ra...,
International, L.P. Elliott,
10% owner
L M Stephenson,
Director
Capital Group Llc Hopkins,
10% owner
Kathleen M O Donnell,
10% owner
Benny Ward,
EVP of Busi. & Strategic Dev.
John Golubieski,
See Remarks